Corporate Action Details
- Bonus Issue Ratio: 2:1 (2 fully paid-up equity shares of ₹10 each for every 1 existing equity share of ₹10 each)
- Eligibility: Shareholders and warrant holders as on the record date (to be determined)
- Approval Status: Recommended by Board of Directors on May 25, 2026, subject to shareholder approval
- Purpose: To reward shareholders for sustained confidence and signal management's confidence in structural earnings growth and long-term scalability
Financial Performance Context
- FY26 Total Revenues: ₹639.12 Crore
- FY26 EBITDA: ₹94.79 Crore
- FY26 PAT: ₹33.21 Crore
Business Operations Context
The company operates as a pharmaceutical formulation manufacturer diversified across:
- Generics (including antihypertensives, antidiabetic, antiretroviral drugs, and narcotics)
- Cosmeceuticals (Bird N Beauty brand)
- Nutraceuticals and dietary/herbal supplements
- Animal healthcare products (integrated platform including Freossi, Wagr, and One Pet Stop)
- Geographic reach: Exports to 52 countries across Africa, Southeast Asia, CIS countries, and Latin America
Capacity Expansion
- Inaugurated 5th GMP-certified manufacturing facility in April 2026
- Provides significant capacity headroom to support scaling across all verticals
Management Commentary
Mr. Fredun Medhora, Managing Director, stated: "The recommendation of a 2:1 bonus issue reflects the strong momentum we have built and our confidence in sustaining this growth trajectory. With robust performance across revenue and profitability, and continued progress in diversifying into higher-value segments such as nutraceuticals, cosmeceuticals and pet healthcare, we are strengthening the quality and scalability of our business."